News Archives for October 2018

Recent News

Full Summary of ASGCT's FDA Liaison Meeting
October 25, 2018
Advocacy Policy Updates

The September 13 liaison meeting between the FDA and ASGCT covered manufacturing, safety, and testing requirements for gene therapies, as well as an FDA update on the new RMAT designation. This deep-dive longread includes the recommendations from those discussions.

President's Message—Abstracts, Value Summit, and ESGCT

The abstract collection is the lifeblood of ASGCT’s Annual Meeting, and the Society is excited to feature the future of our field at the Washington Hilton next year. I encourage all of you to consider submitting your research to the ASGCT Annual Meeting.

ASGCT Submits Comments to CMS on OPPS Proposal
October 09, 2018
Advocacy Policy Updates

ASGCT indicated its support for removal of patient care services from the CAR T-cell therapy Q codes for tisangenlecleucel and axicabtagene ciloleucel to more accurately report, and to obtain more sufficient reimbursement for, administration of these therapies.

22nd Annual Meeting
April 29 – May 2 | Washington D.C.